Longer-term survival with immunotherapy for patients with non–small cell lung cancer (NSCLC) is once again being applauded by experts in the field. This time, the data come from trials that tested ...
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab ...
Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo). Median OS among mRCC patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results